MONROVIA, Calif., June 12, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that the Company will host a R&D Day on Friday, June 26, 2015, from 8:30 a.m. – 11:30 a.m. ET in New York City.
During the R&D day, members of Xencor's management team will provide updates on its XmAb®5871 and XmAb®7195 development programs and its XmAb®14045 and XmAb® bispecific pipeline.
Guest speakers scheduled to attend and present at the event include:
- John H. Stone, M.D., M.P.H.
Professor of Medicine, Harvard Medical School
Director, Clinical Rheumatology, Massachusetts General Hospital - Tyler Curiel, M.D., M.P.H.
Skinner Chair in Cancer Immunotherapy, Professor of Medicine, University of Texas Health Sciences Center San Antonio Cancer Therapy and Research Center
Team Leader, Phase 1 Clinical Trials
Webcast Information
A live audio webcast of the presentation will be available under the "Events & Presentations" section in the Investors section of the Company's website located at http://investors.xencor.com/events.cfm. A replay of the presentation will be posted on the Xencor website approximately one hour after the live event and will be available for 30 days following the presentation.
About Xencor, Inc.
Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases and cancer. Currently, eight candidates that have been engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's internally-discovered programs include: XmAb5871, which completed a Phase 1b/2a clinical trial for the treatment of rheumatoid arthritis and is in preparation for a clinical trial in IgG4-related disease in 2015; XmAb7195 in Phase 1a development for the treatment of asthma; and XmAb5574/MOR208 which has been licensed to Morphosys AG and is in Phase 2 clinical trials for the treatment of acute lymphoblastic leukemia and non-Hodgkin lymphoma. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. Xencor partners include Merck, Janssen R&D LLC, Alexion, Novo Nordisk and Boehringer Ingelheim. For more information, please visit www.xencor.com.
Investor Contact:
John Kuch, Vice President Finance, Xencor
Tel: 626-737-8013
[email protected]
Corporate Communications Contact:
Jason I. Spark, Canale Communications for Xencor
Tel: 619-849-6005
[email protected]
SOURCE Xencor, Inc.
Share this article